Radioactive Iodine

Class: Radiopharmaceutical (β- and γ-emitter).

Mechanism:

  • Thyroid follicular cells actively uptake iodine via the sodium-iodide symporter (NIS).
  • I-131 delivers localized β-radiation → destroys thyroid tissue or residual/ metastatic differentiated thyroid cancer cells.
  • The γ-emission allows post-treatment imaging.

Clinical Indications

Administration / Preparation

  • Oral capsule or liquid (I-131).
  • Pretreatment preparation:
    • Thyroid hormone withdrawal (levothyroxine stopped ~2–4 weeks) OR recombinant TSH (thyrotropin alfa, Thyrogen®) to increase TSH and stimulate iodine uptake.
    • Low-iodine diet for 1–2 weeks before therapy.
  • Dosing (varies by indication, patient size, institutional protocols):
    • Ablation after thyroidectomy: ~30–100 mCi.
    • Metastatic disease: 100–200 mCi.
    • Hyperthyroidism: 5–15 mCi (smaller doses).

Adverse Effects

  • Short-term:
  • Long-term:
    • Hypothyroidism (almost universal in hyperthyroidism treatment).
    • Secondary malignancies (rare, leukemia or solid tumors at high cumulative doses).
    • Infertility (dose-dependent, more concern in younger patients).
    • Pulmonary fibrosis (if lung mets + high dose).

Precautions / Counseling

  • Radiation safety: avoid close contact with children and pregnant women for several days after dose; follow strict hygiene rules.
  • Contraindicated in pregnancy and breastfeeding.
  • Encourage hydration and sour candies to stimulate salivary flow (reduce sialadenitis).

Pharmacist Pearls

 

  • RAI is not effective in medullary or anaplastic thyroid cancers (these do not uptake iodine).
  • Always confirm pregnancy status before administration.
  • Check if patient is on amiodarone or iodinated contrast (can block uptake).
  • Long-term thyroid hormone replacement (levothyroxine) is usually needed.
Links